News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fluorinov Pharma, FACIT And OICR Announce Novel Candidate Drugs Modulating NaV 1.8, NaV 1.7 Sodium Channels For The Safer Treatment Of Cancer Pain And Brain Cancer-Related Epilepsy


4/25/2014 7:53:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Fluorinov Pharma, an emerging Ontario-based drug development company, has developed three structurally distinct candidate drugs that selectively target pain-specific nerve sodium channels (Nav 1.8 and Nav 1.7), intended to treat cancer pain and brain cancer-related epilepsy, announced Malik Slassi, PhD, Chief Scientific Officer. The candidate drugs have shown an excellent preliminary safety profile, improved treatment of pain and epilepsy and are expected to have fewer sedative side effects compared to the current standard of treatment.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES